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Objectives The aim of this study was to evaluate whether thrombectomy during primary percuta-
neous coronary intervention (pPCI) in patients with high thrombus burden improves myocardial rep-
erfusion and reduces infarct size.
Background Thrombectomy aims at reducing distal thrombotic embolization during pPCI, improv-
ing myocardial reperfusion and clinical outcome.
Methods We randomized 208 patients with high thrombus burden in a 1:1 ratio to either pPCI with
thrombectomy (Group T) or standard pPCI (Group S). Thrombectomy was performed with either
rheolytic or manual aspiration catheters. Three-month magnetic resonance imaging was performed
to assess infarct size and transmurality and microvascular obstruction (MVO). The primary endpoints
were ST-segment elevation resolution (STR) 70% at 60 min and 3-month infarct size.
Results The baseline proﬁle was similar between groups, except for a higher rate of initial Throm-
bolysis In Myocardial Infarction ﬂow grade 3 in Group S (p  0.002). Group T showed a signiﬁcantly
higher rate of STR (57.4% vs. 37.3%; p  0.004) and of ﬁnal myocardial blush 3 (68.3% vs. 52.9%;
p  0.03). Group T and Group S did not differ with regard to infarct size (20.4  10.5% vs. 19.3 
10.6%; p  0.54) and transmurality (11.9  12.0% vs. 11.6  12.7%; p  0.92), but Group T showed
signiﬁcantly less MVO (11.4% vs. 26.7%; p  0.02) and a higher prevalence of inhomogeneous scar
(p  0.0001). One-year freedom from major adverse cardiac events was similar between groups.
Conclusions Thrombectomy as an adjunct to pPCI in patients with high thrombus load yielded bet-
ter post-procedural STR and reduced MVO at 3 months but was not associated with a reduction in
infarct size and transmurality. Thromboaspiration in Patients With High Thrombotic Burden Under-
going Primary Percutaneous (Coronary Intervention; NCT01472718) (J Am Coll Cardiol Intv 2012;5:
1223–30) © 2012 by the American College of Cardiology Foundation
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1224Primary percutaneous coronary intervention (pPCI) is
highly effective in restoring a normal Thrombolysis In
Myocardial Infarction (TIMI) flow in patients with ST-
segment elevation acute myocardial infarction (STEMI),
but a relevant proportion of patients shows a poor myocar-
dial reperfusion, which strongly correlates with larger infarct
size and worse clinical outcome (1). Thrombectomy devices
aim at improving myocardial reperfusion by preventing
distal thrombus embolization during pPCI. After contro-
versial results of the initial studies, 2 recent randomized
single-center studies (2,3) demonstrated a significant benefit
of thrombus aspiration on clinical outcome although not on
infarct size. Currently, magnetic resonance imaging (MRI)
with late gadolinium enhancement (LGE) is the best method
to assess infarct size (4) but was
used only in a substudy of a
single-center randomized trial on
thrombectomy (5). Moreover, all
thrombectomy studies until now
included patients with variable de-
grees of thrombus load, leaving
open the question of whether the
benefits of routine thrombus aspi-
ration could be obtained also with
a strategy of selective thrombec-
tomy in patients with large
thrombus burden.
Our aim was to assess the
impact of thrombectomy, either
manual or rheolytic, on myocar-
dial reperfusion and infarct size
in patients with high thrombotic
burden.
Methods
Study design and patients. The
MUSTELA (MUltidevice throm-
bectomy in acute ST ELevation
Acute myocardial infarction)
trial was a multicenter prospective randomized study that
assigned patients in a 1:1 ratio to either thrombectomy as an
adjunct to pPCI (Group T) or standard pPCI without
thrombectomy (Group S). Inclusion criteria were age 18
years; STEMI (new ST-segment elevation of 1 mm in at
least 2 contiguous leads or new left bundle branch block)
within 12 h of symptom onset; TIMI thrombus grade 3
after reclassification of initial grade 5 after coronary recan-
alization with a guidewire or small balloon according to
Sianos et al. (6); and reference diameter of the infarct-
related artery 3.0 mm at visual estimate. Exclusion criteria
were previous infarct in the same ventricular wall; cardio-
genic shock; severe liver/renal failure; contraindications to
Abbreviations
and Acronyms
cTFC  corrected TIMI
frame count
LGE  late gadolinium
enhancement
LV  left ventricular
MACE  major adverse
cardiac events
MBG  myocardial blush
grade
MRI  magnetic resonance
imaging
MT  manual thrombectomy
MVO  microvascular
obstructionp
pPCI  primary percutaneous
coronary intervention
RT  rheolytic thrombectomy
STEMI  ST-segment elevation
myocardial infarction
STR  ST-segment elevation
resolution
TIMI  Thrombolysis In
Myocardial Infarctionabciximab; and contraindications to MRI. Patients showinga TIMI thrombus grade 3 at diagnostic angiography
underwent stratification for infarct location on the anterior
versus non-anterior left ventricular (LV) wall and were
randomized on the basis of computer-generated random
sequence through a dedicated website.
The study was approved by the local Ethics Committee,
and written informed consent was obtained from all patients
before diagnostic angiography (clinical trial unique identi-
fier: NCT01472718; see note after abstract).
PCI procedure. The PCI was performed with standard
technique, with the radial approach as first choice. Throm-
bectomy was performed with either the manual aspiration
Export catheter (Medtronic CardioVascular, Santa Rosa,
California) or the RT AngioJet Ultra catheter (Possis
Medical, Inc., Minneapolis, Minnesota) in a sequential alter-
nating fashion. The thrombectomy catheter was activated just
proximal to the culprit lesion and was slowly pushed across the
lesion for at least 2 passages; additional passages were per-
formed until no further reduction in thrombus load could be
obtained. Pre-dilation with small balloons was performed only
if the thrombectomy catheter failed to cross the lesion. Direct
stenting was recommended, whereas choice of coronary stents
was left at the discretion of the physician. Use of embolic
protection devices was not allowed.
All patients received IV aspirin 250 mg and clopidogrel
600 mg oral load at time of STEMI diagnosis. In the
catheterization laboratory, IV boluses of unfractionated
heparin (60 U/kg body weight) and abciximab (0.25 mg/kg)
were administered, followed by a12-h abciximab infusion at
0.125 g/kg/min. The activated clotting time was kept in
the 200- to 250-s range during pPCI.
Angiographic and electrocardiographic analysis. All angio-
rams were analyzed by 2 experienced investigators in our
ore laboratory in Pisa University Hospital. We assessed the
nitial and post-procedural TIMI flow grade, corrected
IMI frame count (cTFC), and myocardial blush grade
MBG) (7–8). Thrombotic burden was graded according to
he TIMI thrombus classification modified according to
ianos et al. (6). Complete thrombus removal by thrombec-
omy was defined by a reduction in thrombus grade from
rade 4 to grade 0 to 1. Procedural success was defined as a
nal TIMI flow grade 3 with a residual stenosis 20%.
The ST-segment elevation was measured 40 ms after the
point, and the sum of ST-segment deviations was deter-
ined on a 12-lead electrocardiogram before and 60 min
fter intervention. The ST-segment elevation resolution
STR) was categorized as complete (70%), partial (30% to
0%), or absent (30%) (9).
MRI protocol. Three months after PCI, MRI was per-
formed with a 1.5-T scanner with an 8-element cardiac
phased array receiver surface coil (CVi, HD release; GE
Healthcare, Milwaukee, Wisconsin). Left ventricular func-
tional parameters were obtained from short-axis cine images
from mitral valve plane to the apex, with a steady-state free
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1225precession pulse sequence. Rest myocardial perfusion im-
ages were acquired during 30 to 40 consecutive heartbeats,
immediately after administration of a 0.1-mmol/kg bolus of
Magnevist (Schering, Berlin, Germany); a CASH2 (Cali-
bration Slice using Hybrid Acquisition) pulse sequence was
used, and 3 short-axis planes (at basal, mid, and apical level)
were acquired. An additional bolus of 0.1 mmol/kg of
Magnevist was injected immediately after the acquisition of
perfusion images. Early enhancement images were acquired
in the same short- and long-axis slices used for cine-MRI,
with a fast Gradient Echo Inversion Recovery sequence.
Late-enhancement images were obtained 10 min after the
injection of contrast medium in the same acquisition planes.
The inversion recovery time was optimized to nullify the
signal from normal myocardium.
All MRIs were performed and analyzed in Pisa by 2
expert cardiologists blinded to the randomization status of
the patient. We used a previously validated software to
measure LV volumes and mass (Mass, MEDIS, Leiden, the
Netherlands). To assess infarct size, in all short-axis images
the myocardial contours and LGE boundaries were traced
manually; when islands of viable myocardium were identi-
fied within the scar (see following), the extent of LGE was
corrected by subtracting their area, measured with a semi-
automatic, previously validated software (10) (Fig. 1). We
expressed infarct size as percentage of LV mass.
To measure infarct transmurality, we divided the myo-
cardium according to the standard 17-segment model. Each
segment was then divided into 100 chordae, perpendicularly
directed from the endocardial to the epicardial border; LGE
was calculated automatically in each chorda and defined as
transmural when it spanned 75% of myocardial thickness.
Figure 1. Infarct Size Measurement With Late Gadolinium-Enhancement
Magnetic Resonance
(Top) Measurement of left ventricular mass by manual tracing. (Bottom)
Semiautomatic gray-scale analysis of the transmural scar (red area withinw
the interventricular septum).Those segments with transmural LGE in most of their
chordae were considered to have transmural LGE. The LGE
extension and transmurality in the apical cap was calculated
from long-axis images. Finally, transmurality was calculated as
the percentage of segments with transmural LGE.
Microvascular obstruction (MVO) was defined as the
presence of hypo-intense areas within the infarct core scar
characterized by enhanced myocardium in LGE images.
The presence of scar inhomogeneity in segments without
MVO was assessed with a semiautomatic detection algo-
rithm previously described (10). Briefly, we considered areas
of unenhanced myocardium, defined with a signal-intensity
threshold of 6 SD above mean reference signal intensity,
inside the scar as islands of viable myocardium (Fig. 2).
Infarct inhomogeneity was defined by the presence of
islands of viable myocardium covering 5% of myocardial
scar. Interobserver and intraobserver coefficients of varia-
tion, assessed in 25 consecutive patients, were 3% and 2%
for both infarct size and MVO, respectively.
Follow-up. Follow-up visits were scheduled at 1, 6, and 12
months after pPCI. We assessed the 1-year rate of major
adverse cardiac events (MACE), defined as a composite of
death, reinfarction, and target vessel revascularization.
Study endpoints. The primary endpoints were: 1) the rate
f complete STR at 60 min after pPCI, and 2) infarct size
t 3 months.
The secondary endpoints were: 1) post-procedural TIMI
ow grade; 2) post-procedural MBG; 3) infarct transmu-
ality at 3 months; 4) MVO at 3 months; and 5) 1-year
ctuarial freedom from MACE.
Statistical analysis. Continuous variables are presented as
mean  SD or as median (interquartile range) and were
compared with 2-tailed Student t test or Mann–Whitney
test, as appropriate. Categorical variables were compared by
2 or Fisher exact test, as appropriate. The cumulative inci-
ences of MACE at follow-up were assessed with the Kaplan–
eier method, and the log-rank test was used for comparison
etween groups. The analysis was performed on the basis of
he intention-to-treat. All probability values reported are
-sided, and a probability value 0.05 was considered signif-
cant. To adjust for baseline TIMI flow grade 3, we performed
post hoc analysis of covariance on infarct size by randomiza-
ion status, with baseline TIMI flow grade 3 as covariate.
Sample size calculation with regard to the first primary
ndpoint was based on an expected prevalence of complete
TR of 58% in the thrombectomy group and of 37% in the
ontrol group (11); thus 85 patients were required in each
roup to detect such difference with a power of 80% and a
-sided alpha value of 0.05. Concerning the second primary
ndpoint, we expected an infarct size of 15  9% in the
tandard pPCI group (12) and an infarct size of 11  9% in
he thrombectomy group, assuming an infarct size reduction
f 20%. Consequently, a sample size of 80 patients/group
as required to detect the difference with a power of 80%
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1226and a 2-sided alpha value of 0.05. Assuming a 10% attrition
rate for MRI, we scheduled to enroll 88 patients/group. All
data were processed with the Statistical Package for Social
Sciences (version 15; SPSS, Chicago, Illinois).
Results
Study population. We randomized 208 patients to either
thrombectomy (n  104) or standard pPCI (n  104). The
flow of participants through the study is represented in
Figure 3. Baseline clinical characteristics were similar be-
tween groups (Table 1). Importantly, the rate of anterior wall
STEMI was balanced, because of stratification before random-
ization, and also the rate of 3-vessel disease, the angiographic
area at risk, and the LV ejection fraction were similar between
groups. A trend to a shorter pain-to-balloon time in Group S
was observed (p 0.07). Of note, baseline TIMI flow grade 3
as significantly more frequent in Group S (16.3% vs. 3.8%,
 0.002), with a lower cTFC (p  0.005).
Procedural results. The radial approach was used in 95.2%
of patients. Fifty-four patients (51.9%) in Group T under-
went rheolytic thrombectomy (RT), and 50 (48.1%) under-
went manual thrombectomy (MT). Balloon pre-dilation of
the culprit lesion was necessary to allow lesion crossing with
the thrombectomy catheter in only 4 patients (3.8%),
2/group. The thrombectomy catheter could not be delivered
to the culprit lesion because of vessel tortuosity only in 1
MT patient, who was then successfully treated with RT. No
Figure 2. Scar Homogeneity Assessment With Late Gadolinium-Enhanceme
(Left) Large posterolateral transmural infarction containing only scar tissue (“h
areas of viable myocytes within the scar (“inhomogeneous scar”; arrowheads)thrombectomy catheter-associated complications were ob-served; in particular, there was no need for temporary pacing
with RT. Among patients undergoing MT, atherothrom-
botic material was retrieved in 41 (82.0%).
The use of thrombectomy allowed a significantly higher
rate of direct stenting in Group T (74.8% vs. 47.6%; p 
0.0001), with no difference in stent number and length. Group
T showed a significantly higher rate of final MBG 3 (68.3% vs.
52.9%; p  0.03), a lower rate of final TIMI flow grade 2
(6.7% vs. 15.4%; p 0.04), and a trend to a higher rate of final
TIMI flow grade 3 (90.4% vs. 81.7%; p  0.07) (Table 2).
Final cTFC was similar between groups but improved more in
Group T with respect to baseline (p  0.006).
The primary endpoint of complete STR was reached in a
significantly higher proportion of patients in Group T
(57.4% vs. 37.3%; p  0.004).
MRI results. Seventy-nine patients (76.0%) of Group T and
5 (72.1%) of Group S underwent 3-month MRI; the most
ommon reasons for missing MRI analysis were withdrawal
f consent and death before 3 months (Fig. 3). Infarct size was
imilar between groups (20.4  10.5% vs. 19.3  10.6%,
roup T vs. Group S, respectively; p  0.54) as well as
ransmurality (11.9 12.0% vs. 11.6 12.7%; p 0.92) (Fig.
4, Table 3). However, a lower prevalence of MVO was found
in Group T (11.4% vs. 26.7%; p  0.02), together with a
higher rate of inhomogeneous myocardial scar (35.4% vs. 2.7%;
p  0.0001). Left ventricular ejection fraction, end-diastolic
volume, and stroke volume were similar between groups.
In the present study, a higher baseline TIMI flow was
associated with a smaller infarct size (p 0.03); this fact could
gnetic Resonance
eneous scar”; arrow). (Right) Septal transmural infarction with interspersednt Ma
omoghave favored Group S patients, who showed a significantly
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1227higher baseline TIMI flow, masking a potentially significant
reduction in infarct size with thrombectomy. However, after
adjustment for baseline TIMI flow by means of analysis of
covariance, the esteemed infarct size was still similar between
groups (20.3% vs. 19.7%, Group T vs. Group S; p  0.88).
MT versus RT. The rate of complete thrombus aspiration
was higher with RT versus MT (94.4% vs. 78.0%; p 
0.02). No statistically significant differences were observed
between the 2 devices with regard to the primary and
secondary study endpoints; however, a trend toward a
smaller infarct size was observed in the 41 patients treated
with RT who underwent 3-month LGE-MRI versus the 38
treated with MT (17.5 9.6% vs. 21.3 11.3%; p 0.10).
One-year outcome. One-year follow-up was 98.6% com-
plete, with only 1 patient of Group T and 2 of Group S
being lost. Ninety-eight patients of Group T and 97 of
Group S reached the 1-year follow-up. In Group T, 5
patients died because of cardiac causes, 2 suffered reinfarc-
tion (treated with PCI in 1 case), and 1 underwent target
vessel revascularization. In Group S, 4 patients died because
of cardiac causes, 1 died because of hepatic cancer, 2 suffered
reinfarction (treated with PCI in both cases), and 1 under-
Figure 3. Study Design
MRI  magnetic resonance imaging.went target vessel revascularization. The actuarial freedomfrom MACE was 91.4  2.8% in Group T versus 90.2 
2.9% in Group S (p  0.97) (Fig. 5).
Discussion
The present study is the first to assess the impact of
thrombus aspiration on infarct size assessed with MRI in a
large cohort of patients with high thrombotic burden.
Although such patients are the best candidates to benefit
most from thrombectomy, we did not observe a significant
advantage of thrombus aspiration over standard pPCI in
terms of infarct size and transmurality at 3-month follow-
up. However, thrombectomy was associated with better
myocardial reperfusion in terms of STR, MBG, and MVO.
Thrombectomy during pPCI. Distal thrombotic emboliza-
tion, occurring in approximately 15% of patients undergoing
pPCI (13), is 1 of the mechanisms leading to unsuccessful
myocardial reperfusion after pPCI, and numerous types of
thrombectomy devices have been developed to prevent it.
Initial single-center studies reported positive results with
thrombectomy devices when “soft” endpoints, such as post-
PCI TIMI flow, MBG, or STR were used (11,14,15).
However, the first multicenter randomized studies failed to
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1228demonstrate positive outcomes in terms of “hard” clinical
endpoints and also with regard to infarct size (12,16,17).
More recently, the single-center TAPAS (Thrombus Aspi-
ration during Percutaneous coronary intervention in Acute
myocardial infarction Study) (2) and JETSTENT (AngioJet
Rheolytic Thrombectomy Before Direct Infarct Artery
Stenting in Patients Undergoing Primary PCI for Acute
Myocardial Infarction) (3) randomized studies demon-
strated a significant benefit of aspiration thrombectomy on
Table 1. Baseline Characteristics
Thrombectomy
(n  104)
Standard
(n  104) p Value
Age, yrs 62.4 (54.4–69.6) 63.0 (52.9–71.4) 0.72
Male sex 88 (88.4) 79 (76) 0.83
Diabetes 20 (19.2) 21 (20.4) 0.83
Hypertension 54 (51.9) 49 (47.6) 0.53
Dyslipidemia 54 (51.9) 45 (43.7) 0.23
Current smoker 50 (48.1) 51 (49.5) 0.81
Chronic renal failure 3 (2.9) 5 (4.9) 0.46
Pain-to-balloon-time, min 230 (134–294) 208 (148–271) 0.07
Maximum ST-segment elevation, mm 4 (3–5) 4 (3–5) 0.25
Total ST-segment elevation, mm 12 (8–15) 10 (7–15) 0.21
Anterior myocardial infarction 49 (47.1) 48 (46.2) 0.89
3-vessel disease 14 (13.5) 9 (8.7) 0.27
Killip class 3 4 (3.8) 9 (8.7) 0.10
Left ventricular ejection fraction, % 46 8 46 10 0.92
Initial TIMI ﬂow: 0–1 95 (91.3) 81 (77.9) 0.007
2 5 (4.8) 6 (5.8) 0.70
3 4 (3.8) 17 (16.3) 0.002
Initial cTFC 95 17 86 28 0.005
Values are n (%), median (interquartile range), or mean SD.
cTFC corrected TIMI frame count; TIMI Thrombolysis In Myocardial Infarction.
Table 2. Procedural Results
Thrombectomy
(n  104)
Standard
(n  104) p Value
Direct stenting 77 (74.8) 49 (47.6) 0.0001
Total stent length, mm 19 (16–24) 20 (16–24) 0.95
Stent/patient 1.22 0.50 1.17 0.38 0.76
Final TIMI ﬂow: 0–1 3 (2.9) 3 (2.9) 0.68
2 7 (6.7) 16 (15.4) 0.04
3 94 (90.4) 85 (81.7) 0.07
Final cTFC 18 (12–29) 21 (14–33) 0.22
cTFC reduction from baseline 80 (65–87) 71 (34–83) 0.006
Final MBG: 0–1 11 (10.6) 16 (15.4) 0.41
2 22 (13.5) 33 (31.7) 0.12
3 71 (68.3) 55 (52.9) 0.03
Procedural success* 94 (90.4) 85 (81.7) 0.07
ST-segment resolution 70% 58 (57.4) 38 (37.3) 0.004
Values are n (%) or median (interquartile range). *Residual stenosis30% and TIMI flow grade 3.
cTFC corrected TIMI frame count; MBGmyocardial blush grade; TIMI Thrombolysis InMyocardial Infarction.clinical outcomes, although no significant reduction in
infarct size was demonstrated. Based mainly on the TAPAS
trial, MT is currently recommended in all patients under-
going pPCI (18), although it is reasonable to assume that
thrombus aspiration can be useful mainly in patients with
large thrombus burden, which is an independent predictor
of distal embolization during pPCI (13).
The correct assessment of infarct size in trials investigat-
ing thrombectomy during pPCI is of paramount impor-
tance, because the mechanism leading to a reduced mortal-
ity presumably should be a favorable effect on infarct size
(4). Interestingly, all randomized trials failed to demonstrate
a significant reduction in infarct size with thrombectomy,
whatever the technique used for its assessment
(2,3,5,12,16,17). Currently, LGE-MRI is the best tech-
nique for the assessment of infarct size and also allows
measurement of transmurality and MVO (4,19,20). The
only randomized study on thrombectomy that used LGE
for infarct size was the single-center EXPIRA (thrombec-
tomy with export catheter in infarct-related artery during
primary percutaneous coronary intervention) trial (5), where
Figure 4. Infarct Size and Transmurality
Infarct size and transmurality at 3 months, Thrombectomy (red bars) ver-
sus No Thrombectomy (blue bars). LV  left ventricular.
Table 3. MRI Results
Thrombectomy
(n  79)
Standard
(n  75) p Value
Infarct size, % of LV mass 20.4 10.5 19.3 10.6 0.54
Transmural infarct, % of LV segments 11.9 12.0 11.6 12.7 0.92
Microvascular obstruction, n 9 (11.4) 20 (26.7) 0.02
Inhomogeneous scar, n 28 (35.4) 2 (2.7) 0.0001
LV ejection fraction, % 56 12 59 11 0.10
LV end-diastolic volume, ml/m2 82 24 79 20 0.47
LV stroke volume, ml/m2 45 11 45 12 0.75
Values are n (%) or mean SD.LV left ventricular; MRImagnetic resonance imaging.
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1229a subgroup a 72 patients underwent MRI at 3 days and 3
months after pPCI.
Procedural results. Compared with standard pPCI, adjunc-
ive thrombectomy was associated with a significant reduc-
ion in the rate of final TIMI flow grade 2 (p  0.04) and
ith a higher improvement in cTFC with respect to
aseline (p  0.006), possibly reflecting a better myocardial
eperfusion. Moreover, by clearing up the culprit lesion,
hrombectomy allowed a higher rate of direct stenting (p 
.0001), although we did not confirm the slight reduction in
he number of stents/patient previously reported (3).
Myocardial reperfusion. Our study showed a clear advantage
of thrombectomy on surrogate markers of reperfusion at tissue
level, with a complete STR of 57.4% of Group T patients
versus 37.3% of Group S (p  0.004), in agreement with
revious studies reporting complete STR between 56.6% and
7.6% (5,14,21). Final MBG 3 was also significantly improved
n Group T (p 0.03), with a 68% rate falling within the wide
ange of 46% to 88% previously described (3,5,14,21). The
ange of MBG 3 rates reported in thrombectomy trials
nderlines the high interobserver variability of this method.
LGE-MRI. Our trial was designed to maximize the potential
benefits of thrombectomy on infarct size, overcoming some
limitations of previous trials. To this aim, we enrolled only
patients with a high thrombus load, stratified patients
according to infarct location, used a uniform antiplatelet
regime and procedural technique, and assessed infarct size
with LGE. Moreover, we assessed infarct size at 3 months
after pPCI, when myocardial edema has resolved, whereas
previous studies measured LGE at 2 to 5 days, when
myocardial edema is relevant and might be misjudged as
necrotic myocardium (5). However, infarct size and trans-
murality in our trial were similar between groups. Although
Figure 5. Freedom From MACE
Kaplan-Meier estimates of 1-year freedom from major adverse cardiac
events (MACE). Red line indicates Thrombectomy group; blue line indi-
cates No Thrombectomy group.all previous randomized trials on thrombectomy failed todemonstrate a significant reduction in infarct size
(2,3,5,12,16,17), we expected to find an advantage in high-
thrombus-load patients. To explain our findings, we can
advance 2 hypotheses: 1) thrombectomy gives no real reduction
in infarct size when added on top of full antiplatelet therapy
(clopidogrel 600 mg and abciximab bolus), even in patients
with high thrombus load, at least in case of a median
pain-to-balloon time over 3 h; and 2) the possible reduction in
infarct size with thrombectomy was masked by the less
favorable clinical profile of the thrombectomy group with
regard to initial TIMI flow grade 3 (p  0.002) and pain-to-
balloon time (p 0.07). These findings seriously question the
hypothesis that the benefit of thrombectomy on clinical out-
come might derive from a significant reduction in infarct size
and weaken the recommendation for its routine use in pPCI.
The presence of MVO early after STEMI has been
recently demonstrated to be an independent predictor of LV
remodeling (19) and of adverse clinical events (20), with
incremental value above traditional prognostic markers,
such as STR, TIMI flow, infarct size, and transmurality. In
our study, MVO occurred in a significantly lower propor-
tion of patients in the thrombectomy group (p  0.02),
reflecting a less-severe microvascular injury. The absolute
rates of MVO at 3 months were much lower than those
reported when MRI is performed a few days after pPCI,
probably because of scar shrinkage, but still unexpectedly
high, reflecting a persistent microvascular derangement late
after STEMI. Finally, we observed for the first time that
thrombectomy was associated with scar inhomogeneity in
areas without MVO (p  0.0001). However, the clinical
relevance of the presence of islands of viable myocytes inside
necrotic areas is unknown and warrants further investigation.
Clinical outcome. The 1-year actuarial freedom from
ACE was similar between groups (p  0.97), at variance
ith the results of the TAPAS and JETSTENT trials (2,3).
owever, the lack of clinical benefit from thrombectomy in
ur trial agrees with the lack of benefit on infarct size.
MT versus RT. Our trial was not designed to compare RT
versus MT, but the balanced use of the 2 devices allows
exploring the potential differences between them. We de-
scribe for the first time a significantly higher rate of
complete thrombus removal with RT versus MT (p 0.02)
as well as a trend to a smaller infarct size at 3-month LGE
(p  0.10). However, larger randomized studies are man-
datory to verify these preliminary findings. Importantly, no
thrombectomy-related complications were observed with
either device, confirming the high safety profile already
reported for MT (21) and RT (3).
Study limitations. Our study has some limitations. First, the
trial was single-blind, with the operator knowing the ran-
domization assignment; however, the physicians reading
LGE were unaware of randomization assignment. Second,
we enrolled only 65% of the screened STEMI patients,
because of selection criteria. However, excluding patients
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1230with low thrombotic burden is very unlikely to have masked
the benefits of thrombectomy. Third, infarct size assessment
by LGE was performed in only 159 of 208 patients (76.4%),
mainly because of patient withdrawal and patient death
before 3 months. Nevertheless, ours is the thrombectomy
trial with the largest population of patients undergoing
LGE-MRI. Fourth, we did not choose the thrombectomy
device in a randomized fashion, so that inferences on the
comparison between devices can only be hypothesis-
generating. Finally, the imbalance in initial TIMI flow
grade 3 might have disadvantaged the thrombectomy group,
possibly masking a potential benefit; however, after adjust-
ment for this imbalance, we still could not find a significant
reduction in infarct size with thrombectomy.
Conclusions
Thrombectomy as an adjunct to pPCI in patients with high
thrombus load was associated with better myocardial reper-
fusion, in terms of better TIMI flow, higher STR, and
reduced MVO but was not associated with a reduction in
infarct size and transmurality at 3-month MRI or with
better clinical outcome at 1 year. Rheolytic thrombectomy
was more effective than MT in removing thrombus and
showed a nonsignificant reduction in infarct size.
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